Published on
February 22, 2022

Novamind Publishes Psychedelic Therapy Patient Case Studies

TORONTO, ON / ACCESSWIRE / February 22, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today launched Healing Stories, a series of case studies with first-hand accounts of patient experiences with psychedelic-assisted psychotherapy at Novamind clinics ("Healing Stories").

Healing Stories was commissioned by Novamind as part of the Company's ongoing efforts to destigmatize mental illness and to educate the public on psychedelic medicine. While promising data from clinical research and advocacy supported by Novamind and other mission-driven organizations continues to increase awareness and public education, negative perceptions of mental health conditions are frequently cited as a barrier to seeking help.1

Yaron Conforti, CEO and Director, commented, "We know one of the most powerful ways to break down stigma is through sharing lived experiences. Whether they see their own experiences reflected or those of their loved ones, we hope that Healing Stories will resonate and empower people to reach out for help."

The first two Healing Stories feature frontline healthcare workers who found relief through ketamine-assisted psychotherapy (KAP) when the stress of the pandemic destabilized their mental health and exacerbated pre-existing conditions. A third Healing Story features a patient with severe depression who was ready for a new solution after traditional therapy and medications were no longer effective treatment options.

Mr. Conforti continued, "The stories are in the voices of patients who are new to KAP, helping to shed light, dispel fear and educate the public and referring clinicians about this novel treatment option. We're incredibly grateful to everyone who has shared their deeply personal story-it is creating hope for healing."

To read Healing Stories, please visit this link.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit

Contact Information
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications

Investor Relations

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.